Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sgi-1776. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 known ✓ | P11309 | 19/20 | 1.00 |
| ▸ | PIM3 known ✓ | Q86V86 | 2/20 | 1.00 |
| ▸ | PIM2 known ✓ | Q9P1W9 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 0.92 |
| ▸ | STK10 | O94804 | 1/20 | 0.92 |
| ▸ | YES1 | P07947 | 1/20 | 0.92 |
| ▸ | RET | P07949 | 1/20 | 0.92 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.92 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.92 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.92 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.92 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.92 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.92 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.92 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.92 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.92 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.92 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sgi-1776 SCHEMBL29401822 | 1.00 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| Sgi-1776 SCHEMBL102498 | 0.96 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| Sgi-1776 SCHEMBL29353896 | 0.96 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL140271 | 0.89 | PIM1 (0.89) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL103050 | 0.88 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL102377 | 0.87 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL16752577 | 0.87 | PIM1 (0.84) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL102154 | 0.87 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL22421445 | 0.87 | PIM1 (0.80) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL102881 | 0.87 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-12-09 | — | — | US | disclosed |
| US-20250295820-A1 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (IT) | 2025-09-25 | — | — | US | disclosed |
| US-12415003-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-09-16 | — | — | US | disclosed |
| US-20250082790-A1 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (IT) | 2025-03-13 | — | — | US | disclosed |
| US-20250082791-A1 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (IT) | 2025-03-13 | — | — | US | disclosed |
| US-20250049969-A1 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (IT) | 2025-02-13 | — | — | US | disclosed |
| US-20250025583-A1 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-01-23 | — | — | US | disclosed |
| US-12168063-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2024-12-17 | — | — | US | disclosed |
| US-12161732-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2024-12-10 | — | — | US | disclosed |
| US-12151003-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2024-11-26 | — | — | US | disclosed |
| US-10596278-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (IT) | 2020-03-24 | — | — | US | disclosed |
| US-10596276-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (IT) | 2020-03-24 | — | — | US | disclosed |
| US-20200030466-A1 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2020-01-30 | — | — | US | disclosed |
| US-20200030464-A1 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2020-01-30 | — | — | US | disclosed |
| US-20200030467-A1 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2020-01-30 | — | — | US | disclosed |
| WO-2020021465-A1 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (IT) | 2020-01-30 | — | — | WO | disclosed |
| EP-3274344-B1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | NOVARTIS PHARMA AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS PHARMA AG (CH) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082790-A1 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-20200030467-A1 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-20200030464-A1 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-12415003-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | FGFR4, FGFR1, FGFR3 | PIM1 584/4885PIM3 810/4885PIM2 706/4885 |
| US-20250049969-A1 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-10596278-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-20250025583-A1 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | IL15RA, IL15, SSTR5 | PIM1 1189/4885PIM3 925/4885PIM2 2357/4885 |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | PIM1 537/4885PIM3 786/4885PIM2 656/4885 |
| US-12161732-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-20200030466-A1 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-12168063-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | PIM1 537/4885PIM3 786/4885PIM2 656/4885 |
| US-20250295820-A1 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-10596276-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-20250082791-A1 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
| US-12151003-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | PIM1 3415/4885PIM3 3149/4885PIM2 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.